Massive Real-World study investigates rare eye inflammation after common injection
NCT ID NCT07105228
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed data from nearly 290,000 patients who received aflibercept (Eylea) injections for various retinal diseases. The goal was to estimate how often retinal vasculitis (inflammation of blood vessels in the eye) occurs in real-world clinical practice. Researchers looked at medical records from 2017 to 2024 to identify cases and describe patient characteristics.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept (Eylea)
- What this could lead to
- If successful, this study could help doctors better understand the risk of retinal vasculitis in patients receiving aflibercept injections.
- What could go wrong
- This is an observational study using existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regeneron Research Site
Tarrytown, New York, 10591, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.